Omada Health shares surge 6.83% pre-market ahead of J.P. Morgan Healthcare Conference on Jan. 14 2026

Generated by AI AgentAinvest Pre-Market RadarReviewed byDavid Feng
Tuesday, Dec 23, 2025 5:34 am ET1min read
Aime RobotAime Summary

-

Health's shares rose 6.83% pre-market ahead of its Jan. 14 J.P. Morgan Conference presentation.

- The company will showcase its AI-human hybrid care model targeting diabetes, obesity, and GLP-1 therapy patients.

- With 1M+ members and 30+ peer-reviewed studies, Omada aims to highlight its data-driven approach at the influential event.

- The conference, known to boost

stocks, may enhance investor confidence in Omada's virtual care strategy.

Omada Health shares surged 6.8276% in pre-market trading on Dec. 23, 2025, as investor attention turned to the company’s upcoming participation in a major industry event.

The stock’s advance came ahead of the company’s scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026. Senior management will showcase its virtual care model targeting cardiometabolic conditions, including diabetes and obesity, as well as specialized programs for patients using GLP-1 therapies.

Omada’s Compassionate Intelligence platform combines human-led care teams with AI-driven tools to deliver personalized health outcomes. With over a decade of clinical data and 30 peer-reviewed publications, the company has served more than one million members across 2,000 clients, including Fortune 500 employers and health systems.

Investors may be weighing the potential for increased visibility during the high-profile conference, which often serves as a catalyst for biotech and healthcare stocks. The live webcast and replay of the presentation will be available on Omada’s investor relations site, offering stakeholders further insight into its strategic direction.

Comments



Add a public comment...
No comments

No comments yet